Trial · NCT01052272
Results by group252
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 252
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril | Month 0 (n=17,17,18,18) | 73.03 | Standard Deviation 20.34 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil | Month 0 (n=17,17,18,18) | 78.06 | Standard Deviation 18.4 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril and Allopurinol | Month 0 (n=17,17,18,18) | 78.52 | Standard Deviation 19.31 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil and Allopurinol | Month 0 (n=17,17,18,18) | 79.03 | Standard Deviation 21.39 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril | Month 6(n=14,11,11,12) | 74.10 | Standard Deviation 15.53 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil | Month 6(n=14,11,11,12) | 78.60 | Standard Deviation 24.30 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril and Allopurinol | Month 6(n=14,11,11,12) | 86.13 | Standard Deviation 24.14 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil and Allopurinol | Month 6(n=14,11,11,12) | 78.01 | Standard Deviation 14.49 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril | Month 9(n=1,2,0,0) | 73.23 | Standard Deviation NA | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil | Month 9(n=1,2,0,0) | 93.57 | Standard Deviation 18.48 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril and Allopurinol | Month 9(n=1,2,0,0) | NA | Standard Deviation NA | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil and Allopurinol | Month 9(n=1,2,0,0) | NA | Standard Deviation NA | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril | Month12(n=12,11,11,11) | 75.34 | Standard Deviation 20.30 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil | Month12(n=12,11,11,11) | 85.44 | Standard Deviation 20.87 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril and Allopurinol | Month12(n=12,11,11,11) | 83.95 | Standard Deviation 20.69 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil and Allopurinol | Month12(n=12,11,11,11) | 79.75 | Standard Deviation 19.9 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril | Month 15(n=3,2,1,1) | 81.19 | Standard Deviation 5.96 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil | Month 15(n=3,2,1,1) | 90.20 | Standard Deviation 13.24 | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Ramipril and Allopurinol | Month 15(n=3,2,1,1) | 108.25 | Standard Deviation NA | ml/m^2 |
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Candesartan Cilexetil and Allopurinol | Month 15(n=3,2,1,1) | 63.1 | Standard Deviation NA | ml/m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01052272/results